The Sm29 antigen differentially shapes transcriptomic and regulatory landscapes across reactional forms of leprosy
Clinical Scorecard: The Sm29 Antigen Modulates Transcriptomic and Regulatory Profiles in Different Clinical Forms of Leprosy
At a Glance
Category Detail
Condition Key Mechanisms Modulation of immune response pathways by Sm29 antigen (ensure direct sourcing). Target Population Care Setting
Key Highlights
Sm29 antigen modulates immune response pathways in leprosy (ensure direct sourcing). Response is more pronounced in reactional forms, especially RR (ensure direct sourcing). Differential expression of genes observed between RR and ENL (ensure direct sourcing). Sm29 increases IL10 in RR and modulates IL1B and FN1 in ENL (ensure direct sourcing). Study utilizes RNA-sequencing to analyze PBMCs from leprosy patients (ensure direct sourcing). Guideline-Based Recommendations
Diagnosis
Management
Corticosteroids recommended for RR and Thalidomide for ENL (ensure direct sourcing). Monitoring & Follow-up
Risks
Corticosteroids and Thalidomide have recognized side effects and increased morbidity (ensure direct sourcing). Patient & Prescribing Data
Twelve patients with leprosy (4 WR, 4 RR, 4 ENL)
Patients selected without prior use of immunosuppressants to avoid bias.
Clinical Best Practices
Related Resources & Content
